RxDoctor Payments Data

Daniel Sewell, MD

Family Medicine · Auburn, CANPI 1609979723

Payments from drug & device makers

$11,033in general payments, 2019–2025

Across 669 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$1K
  • GSK$1K
  • Pfizer$485
  • Lilly USA, LLC$437
  • Bayer$424
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$11,027100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,033 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$506,142
Medicare patients
872
Services billed
12,280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$172,016
JardianceEmpagliflozin110$143,486
EliquisApixaban126$117,424
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$63,570
RybelsusSemaglutide27$53,082
XareltoRivaroxaban38$47,402
FarxigaDapagliflozin Propanediol31$37,795
MounjaroTirzepatide32$36,406
CreonLipase/Protease/Amylase14$32,647
JanuviaSitagliptin Phosphate22$28,018
MyrbetriqMirabegron32$24,887
Tresiba Flextouch U-200Insulin Degludec15$20,490
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$20,475
TrintellixVortioxetine Hydrobromide23$17,457
Tresiba Flextouch U-100Insulin Degludec28$15,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,459$225,098146 claims
Boehringer IngelheimJardiance, Tradjenta$402$156,826127 claims
PfizerEliquis$485$117,424126 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,177$77,485100 claims
Johnson & JohnsonXarelto$94$47,40238 claims
AbbVieCreon, Linzess$2,561$43,88827 claims
AstraZenecaFarxiga$349$37,79531 claims
Lilly USA, LLCMounjaro$437$36,40632 claims
MerckJanuvia$216$28,01822 claims
Astellas Pharma US IncMyrbetriq$71$24,88732 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$297$17,45723 claims
Collegium Pharmaceutical, Inc.Xtampza Er$260$9,15416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Auburn

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →